Oncology Corporate Profile
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG?s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|C-CAR011||anti-CD19 inhibitor||Acute Myelogenous Leukemia (AML)||I|
|C-CAR011||anti-CD19 inhibitor||Diffuse large B-cell Lymphoma (DLBCL)||I|
View additional information on product candidates here »
3/30/2017 12:04 pm
[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., March 30, 2017-- Cellular Biomedicine Group Inc., a leading clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer ...
3/23/2017 04:02 pm
3/22/2017 03:01 pm
3/21/2017 12:01 pm
[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., March 21, 2017-- Cellular Biomedicine Group Inc., a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem ...